Printed from Voxsanity (voxsanity.com.au) — NCT07307443 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT07307443
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who give their voluntary agreement to take part and sign a written consent form.
- People aged 18 or older.
- People with a life expectancy of at least 3 months.
- People diagnosed with lung cancer that cannot be removed by surgery and is either locally advanced (Stage IIIB) or has spread to other parts of the body (Stage IV), and cannot be treated with curative radiotherapy.
- People whose tumor has been tested and confirmed to be missing the BRG1 protein (related to the SMARCA4 gene).
- People who have not previously received any systemic anti-cancer treatment.
- People whose general physical functioning is rated at 0 or 1 on a standard medical scale (meaning they are fully active or able to carry out light activity), known as ECOG Performance Status.
- People who are willing and able to provide stored or fresh tumor tissue samples for testing; if tissue is not available, the trial site investigator may still consider enrollment if all other criteria are met.
- People who have at least one measurable tumor site, as assessed using a standard medical measurement system.
- People whose blood counts and organ function fall within acceptable ranges, including: sufficient levels of white blood cells, platelets, and haemoglobin (without a blood transfusion in the past 14 days); kidney function within normal limits; liver enzyme levels within normal limits (with slightly higher limits allowed if cancer has spread to the liver); bilirubin levels within normal limits (with a specific allowance for people with a condition called Gilbert's syndrome); and blood clotting measures within normal limits (for people not on blood-thinning medication).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose cancer diagnosis includes a small cell carcinoma component.
- People who have brain metastases that are causing symptoms.
- People who have cancer that has spread to the membranes surrounding the brain and spinal cord (leptomeningeal carcinomatosis).
- People who have not recovered from side effects of previous anti-cancer treatment to an acceptable level within 4 weeks before the first dose (not including hair loss or fatigue).
- People who have difficulty with intravenous access or taking medication by mouth (for example, difficulty swallowing, ongoing diarrhoea, or a bowel blockage), or who are unwilling or unable to have a repeat biopsy or provide enough tissue for detailed testing.
- People who have not recovered from side effects of previous treatments to an acceptable level, except for certain low-risk side effects such as mild hair loss, mild nerve pain, mild anaemia, minor stable lab abnormalities, or a stable thyroid condition managed with medication.
- People who have had major surgery or a serious injury within 4 weeks before the first dose, or who are expected to need major surgery during the study, or who have wounds or fractures that have not healed.
- People who have had a blood clot in an artery or vein (such as a stroke, mini-stroke, deep vein thrombosis, or pulmonary embolism) within 6 months before the first dose, or a serious bleeding event within 4 weeks before the first dose.
- People with poorly controlled active hepatitis B or C, unless specific viral load and treatment conditions are met as assessed by the trial site (confirm with trial site).
- People with a history of substance abuse involving psychotropic substances and who are unable to stop, or people with a psychiatric disorder.
- People who have previously had, or are planning to have, a bone marrow transplant or solid organ transplant from a donor.
- People with a history of hepatic encephalopathy (a condition where liver disease affects brain function).
- People with significant heart disease, including: moderate or severe heart failure; a low heart pumping function on ultrasound; a history of serious heart rhythm problems or those requiring ongoing medication; unstable chest pain (unstable angina); a heart attack in the past 12 months; an abnormally long heart electrical interval (QTcF) on an ECG; a personal or family history of a condition causing a long QT interval from birth; a blood clot in a deep vein, lungs, or elsewhere within 3 months before joining the study; or current or recent use of certain blood-thinning or circulation medications within 7 days before treatment.
- People with poorly controlled ongoing illnesses, including: a serious infection requiring hospitalisation within 4 weeks before treatment, or use of antibiotic treatment (not preventive) within 2 weeks before treatment; symptomatic heart failure or poorly controlled irregular heartbeat; another active cancer diagnosed in the past 5 years (with exceptions for certain fully treated skin or in-situ cancers with no recurrence); suspected or confirmed acute promyelocytic leukaemia (for patients with acute myeloid leukaemia); active cancer spread to the membranes around the brain or spinal cord compression; poorly controlled high blood pressure; symptomatic lung disease; a blood clot in an artery within 6 months before joining; severe malnutrition requiring intravenous nutrition unless stable for at least 4 weeks before the first dose; cancer growing into nearby vital organs or major blood vessels, or risk of an abnormal connection forming between the oesophagus and airway or lung lining; a history of oesophageal or tracheal stent placement; any other illness or lab abnormality that the investigator believes increases risk or affects study results; a history of a hole or abnormal channel in the gastrointestinal tract within 6 months before joining; or uncontrolled fluid build-up in body cavities requiring repeated drainage (unless drainage has stopped and the condition has been stable for at least 3 days).
- People with active gastrointestinal diseases or other conditions that may significantly affect how the body absorbs, processes, or removes the study drug, such as malabsorption syndrome, inflammatory bowel disease, bowel obstruction, or prior removal of the stomach or part of the small bowel.
- People with severe lung disease or a history of it, such as moderate to severe chronic obstructive pulmonary disease, interstitial lung disease, drug-related lung damage, infectious pneumonia, or a prior lung transplant.
- People who are pregnant or breastfeeding.
- People who are currently taking part in another interventional clinical trial, an observational study, or who are in the follow-up phase of another interventional study.
- People with a known history of receiving an organ transplant or bone marrow/stem cell transplant from a donor.
- People who have had major surgery (such as brain, chest, or abdominal surgery, or a vascular procedure) within 4 weeks before the first dose, or who have wounds, ulcers, or fractures that have not healed (minor palliative local surgery may be acceptable — confirm with trial site).
- People who are HIV positive.
- People with a known active syphilis infection or active tuberculosis.
- People with a documented history of a psychiatric condition requiring medication.
- People with a history of drug abuse or substance addiction.
- People with any other condition that the investigator believes may affect study results or make participation unsuitable, including existing or past medical conditions, treatments, or lab findings, or unwillingness to follow study procedures.
- People who have used another investigational drug or therapy within 4 weeks before the first study dose.
- People who have used any Chinese herbal medicine with anti-tumour activity within 2 weeks before starting study treatment.
- People with a history of another cancer (excluding certain skin and in-situ cancers), unless the person has been in complete remission for at least 2 years before joining and does not need other cancer treatment during the study.
- People who have received, or are planned to receive, a live vaccine within 28 days before the first study dose.
- People with a known allergy or intolerance to the study drug or any of its ingredients.
- People who, in the investigator's opinion, are unsuitable to take part in this trial for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
If this is close to home
This page includes language about advanced illness, prognosis, or palliative care, because that is how the trial's eligibility criteria are written. Seeing it set out plainly can land hard, whether it is about you or about someone you are caring for. You do not have to be at a crisis point to talk to someone.
- Griefline — grief and loss counselling, 9am to 6pm weekdays and midday to 6pm weekends (AEST/AEDT): 1300 845 745
- Carer Gateway — practical and emotional support if you are caring for someone, 8am to 5pm weekdays: 1800 422 737
- Canteen — for 12 to 25 year olds affected by cancer, their own or a family member's: 1800 945 215
- Palliative Care Australia — directory of palliative care services near you: palliativecare.org.au
- Lifeline — 24/7, for any kind of distress, at any hour the services above are closed: 13 11 14
Palliative care is not the same as giving up on treatment, and it is not only for the last weeks of life. It is symptom and comfort care that can run alongside active treatment, including a clinical trial.
Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of support and crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention.
Voxsanity is not a counselling or medical service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.
Contact this trial
Phone: +86 13466323860
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Zhijie Wang
Registry
ClinicalTrials.gov
Start date
1 February 2026
Est. completion
1 December 2027
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Progression-Free Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.